Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Rigel Pharmaceuticals

Rigel Pharmaceuticals (NASDAQ: RIGL) insider transactions

In the twelve months to 10 November 2026, executives and directors of Rigel Pharmaceuticals reported 3 open-market sales of 9,000 shares ($305,865) and 0 open-market purchases, by 2 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Rigel Pharmaceuticals shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
2 September 2026Schorno Dean LEVP & Chief Financial OfficerOption exercise+694$12.7079,056Form 4
2 September 2026Schorno Dean LEVP & Chief Financial OfficerOption exercise+620$18.7079,676Form 4
2 September 2026Schorno Dean LEVP & Chief Financial OfficerOption exercise+2,000$24.2081,676Form 4
2 September 2026Schorno Dean LEVP & Chief Financial OfficerOption exercise+1,286$24.2082,962Form 4
1 September 2026Furey Raymond J.EVP, GC, CCO & Corp SecShares withheld for tax−877$47.5050,559Form 4
1 September 2026Rodriguez Raul RCEO, PresidentShares withheld for tax−2,424$47.50273,362Form 4
1 September 2026Santos David AEVP, Chief Commercial OfficerShares withheld for tax−874$47.5061,622Form 4
1 September 2026Schorno Dean LEVP & Chief Financial OfficerShares withheld for tax−928$47.5078,362Form 4
8 July 2026Hannah Alison L.EVP, Chief Medical OfficerGrant or award+24,400—35,025Form 4
22 June 2026Ali-Jackson KamilDirectorOpen-market sale−2,500$35.0010,125Form 4
1 June 2026Furey Raymond J.EVP, GC, CCO & Corp SecShares withheld for tax−877$29.8650,936Form 4
1 June 2026Rodriguez Raul RCEO, PresidentShares withheld for tax−2,424$29.86279,593Form 4
1 June 2026Rojkjaer LisaEVP, Chief Medical OfficerShares withheld for tax−850$29.8634,003Form 4
1 June 2026Santos David AEVP, Chief Commercial OfficerShares withheld for tax−874$29.8661,996Form 4
1 June 2026Schorno Dean LEVP & Chief Financial OfficerOption exercise+1,200$18.7077,537Form 4
1 June 2026Schorno Dean LEVP & Chief Financial OfficerOption exercise+2,181$12.7079,718Form 4
1 June 2026Schorno Dean LEVP & Chief Financial OfficerShares withheld for tax−928$29.8678,790Form 4
26 May 2026Ali-Jackson KamilDirectorOpen-market sale−2,500$29.1712,625Form 4
15 May 2026Ali-Jackson KamilDirectorGrant or award+5,750—15,125Form 4
15 May 2026Frohlich Mark WDirectorGrant or award+5,750—7,000Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Rigel Pharmaceuticals page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.